New model crosses combine amyloid pathology with clinically relevant human APOE genetics to support more translational Alzheimer's disease research.
News Release
Taconic Biosciences Expands Alzheimer's Disease Portfolio with New APOE3 and APOE4 APP/PS1 (ARTE10) Mouse Models
Rensselaer, N.Y. — August 3, 2026 — Taconic Biosciences, Inc., a global leader in genetically engineered rodent models and preclinical research solutions, today announced the launch of two new Alzheimer's disease (AD) mouse models that combine the well-established APP/PS1 (ARTE10) amyloid pathology model with human APOE3 and APOE4 genetic backgrounds. Together, these models provide researchers with complementary tools to investigate both familial and sporadic aspects of Alzheimer's disease biology.
Alzheimer's disease remains one of the most complex neurodegenerative disorders, with multiple genetic and pathological mechanisms contributing to disease onset and progression. While many preclinical models focus on a single disease pathway, researchers increasingly rely on multiple models to better understand disease biology and evaluate potential therapeutics.
The new APOE3xAPP/PS1 (ARTE10) and APOE4xAPP/PS1 (ARTE10) models address this need by combining robust amyloid pathology with clinically relevant human apolipoprotein E (APOE) genetics. APOE4 is the strongest known genetic risk factor for late-onset Alzheimer's disease, while APOE3 represents the most common human isoform and serves as an important experimental control.
"Alzheimer's disease is not a single disease mechanism, and no single preclinical model can answer every research question," said Sarah Sterlace, PhD, Senior Director, Neurobiology, Portfolio Management at Taconic Biosciences. "By combining established amyloid pathology with human APOE genetics, these new models give researchers additional tools to evaluate therapeutic efficacy across more clinically relevant disease biology."
The complementary models enable researchers to:
- Compare therapeutic responses across different human APOE genotypes.
- Investigate interactions between amyloid pathology and genetic risk factors.
- De-risk potential therapeutics by using models that reflect both familial and sporadic Alzheimer's disease biology.
- Strengthen confidence in preclinical findings through comparative study designs.
The new models further expand Taconic's growing neurobiology portfolio, providing researchers with access to a broad range of genetically engineered models supporting Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other neurodegenerative disorders.
"Our goal is to provide researchers with translationally relevant models aged appropriately for experimental-readiness, to answer increasingly complex scientific questions," added Sterlace. "These new additions strengthen our Alzheimer's disease portfolio and reinforce Taconic's commitment to supporting translational neuroscience research."
The new APOE3xAPP/PS1 (ARTE10) and APOE4xAPP/PS1 (ARTE10) models will be available for research use beginning August 21, 2026.
"Alzheimer's disease is not a single disease mechanism, and no single preclinical model can answer every research question. By combining established amyloid pathology with human APOE genetics, these new models give researchers additional tools to evaluate therapeutic efficacy across more clinically relevant disease biology."
Sarah Sterlace, PhD, Senior Director, Neurobiology Portfolio Management, Taconic Biosciences
About Taconic Biosciences
Taconic Biosciences is a global leader in genetically engineered rodent models and associated services, providing innovative research models and scientific expertise to accelerate drug discovery. For more than 70 years, Taconic has partnered with pharmaceutical and biotechnology companies, academic institutions, and government organizations worldwide to advance biomedical research through industry-leading animal models, custom model generation, breeding, colony management, and scientific services.
Media Contact:
Travis LaFavor
Director, Marketing Operations, Taconic Biosciences
marketing@taconic.com